Chronic Kidney Disease - Immune Cell Biology - Co-Op
Boehringer Ingelheim
Summary
Boehringer Ingelheim is currently seeking a talented and innovative Spring Co-Op to join our Cardiovascular-Renal Metabolic Diseases Research department located at our Ridgefield, CT facility. As a Co-Op, you will work with cell differentiation protocols and functional assays to evaluate novel therapeutic concepts. You will be responsible for expanding this department's immune cell related assay toolbox, applying those new methods to test novel hypotheses about disease pathomechanisms.
Job description
Duties & Responsibilities
- Complete a research project focused on developing B cell and iPSC cell differentiation protocols along with functional assays to validate novel therapeutic concepts.
- Forecast and adhere to realistic timelines and goals.
- Understand how your studies support departmental goals.
- Plan and execute experiments and analyze the resulting data.
- Maintain detailed lab notebooks.
- Produce working protocols for others to continue using after your Co-Op period concludes.
- Integrate within the Cardiovascular-Renal Metabolic Diseases Research department and identify collaborators who will benefit from your new techniques.
- Begin collaborations wherein you generate data useful to their projects.
- Communicate your work in lab, group, and departmental presentations.
Requirements
- Must be a current graduate or advanced degree student in good academic standing
- Student must be enrolled at an accredited college or university for the duration of the co-op
- Overall cumulative minimum GPA from last completed quarter/semester 3.0 GPA (on a 4.0 scale) preferred
- Major or minor in related field of co-op
- Graduate and advanced degree students must have completed at least 9 credit hours at current college or university
- Cell line, Primary and iPSC cell culture, aseptic technique
- Basic knowledge of immune cell biology (B cells and macrophages)
- Basic knowledge of data analysis
- Experience in conducting small research projects
- Experience with flow cytometry and immunoassays is preferred
Eligibility Requirements
- Must be legally authorized to work in the United States without restriction
- Must be willing to take a drug test and post-offer physical (if required)
- Must be 18 years of age or older
Requirements
- Must be a current graduate or advanced degree student in good academic standing
- Student must be enrolled at an accredited college or university for the duration of the co-op
- Overall cumulative minimum GPA from last completed quarter/semester 3.0 GPA (on a 4.0 scale) preferred
- Major or minor in related field of co-op
- Graduate and advanced degree students must have completed at least 9 credit hours at current college or university
- Cell line, Primary and iPSC cell culture, aseptic technique
- Basic knowledge of immune cell biology (B cells and macrophages)
- Basic knowledge of data analysis
- Experience in conducting small research projects
- Experience with flow cytometry and immunoassays is preferred
- Must be legally authorized to work in the United States without restriction
- Must be willing to take a drug test and post-offer physical (if required)
- Must be 18 years of age or older
Benefits
- Medical Coverage
- Paid Time Off
- Paid Holidays
- Disability Insurance
- Life Insurance
- Company-Sponsored Benefits
Company overview
Boehringer Ingelheim is a leading global research-driven biopharmaceutical company founded in 1885 and headquartered in Ingelheim am Rhein, Germany. As one of the world's top 20 pharmaceutical companies and the largest privately-owned pharmaceutical firm, it operates across three main business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. The company focuses on developing innovative therapies for diseases with high unmet medical needs, including cardiometabolic diseases, oncology, respiratory diseases, immunology, central nervous system disorders, and retinal health. With over 54,500 employees across 78 countries, Boehringer Ingelheim generated approximately €26.8 billion in revenue in 2024. The company maintains a strong research and development network with facilities in Germany, the United States, Austria, Japan, and Switzerland, investing significantly in advancing treatments for both human and animal health. Notable products include Jardiance (empagliflozin) for diabetes, Ofev (nintedanib) for pulmonary fibrosis, Spiriva (tiotropium) for respiratory conditions, and Pradaxa (dabigatran) for anticoagulation therapy.